research The Role of Janus Kinase Inhibitors in Dermatology
Janus Kinase Inhibitors are promising new treatments for various skin conditions due to their effectiveness and safety.
Search
for
Sort by
Research
210-240 / 1000+ results 
research Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors
Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.
research Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.
research Hair loss and Hedgehog inhibitors: a class effect?
Hedgehog pathway inhibitors used for skin cancer can cause significant hair loss, which may improve after stopping the medication.
research Sustained release of inhibitor from bionic scaffolds for wound healing and functional regeneration
Researchers developed a scaffold that releases a healing drug over time, improving wound healing and skin regeneration.
research Janus Kinase inhibitors in dermatology: a review
JAK inhibitors effectively treat skin conditions and topical forms are safer.
research Janus Kinase Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
research Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
research Curcumin derivatives inhibit testicular 17β-hydroxysteroid dehydrogenase 3
Curcumin and its derivatives can block an enzyme important for making testosterone, with one derivative being particularly strong.
research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
research Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research 139 Anti-BCC efficacy of a topical hedgehog inhibitor without adverse effects in BCNS patients in a phase 2 randomized controlled trial
Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.
research Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.
research Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review
Certain drugs are effective for skin conditions like psoriasis, vitiligo, and hair loss.
research MARIO LACOUTURE: How Do I Treat a Patient with Dermatologic Toxicities to EGFR Inhibitors?
Dr. Mario Lacouture recommends preventive and specific treatments for skin side effects caused by EGFR inhibitors to improve patients' quality of life.
research EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.
research HPLC characterization, molecular docking, QSAR and molecular dynamics simulation of Alstonia boonei phytochemical analogs as potent 5-alpha reductase inhibitors
Alstonia boonei phytochemicals show promise as alternative treatments for BPH with fewer side effects than current drugs.
research Steroid 5α-Reductase Inhibitors
New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
research 12 Treatment of hirsutism with 5α-reductase inhibitors
New compounds may soon be tested to treat excessive hair growth in women.
research Recent Advances in the Chemistry and Pharmacological Activity of New Steroidal Antiandrogens and 5α-Reductase Inhibitors
New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
research 5α-reductase inhibitors
5α-reductase inhibitors help treat disorders caused by DHT and have potential for future therapies.
research Glycogen Phosphorylase Inhibitor Promotes Hair Growth via Protecting from Oxidative-Stress and Regulating Glycogen Breakdown in Human Hair follicles
A new compound, HTPI, promotes hair growth by protecting cells from damage and regulating energy use.
research <p>Comparison of the Therapeutic Effect of Allogeneic and Xenogeneic Small Extracellular Vesicles in Soft Tissue Repair</p>
Both human and animal-derived small extracellular vesicles speed up skin healing equally well.
research Selective induction of apoptosis in the hamster flank sebaceous gland organ by a topical liposome 5-α-reductase inhibitor: A treatment strategy for acne
A topical treatment safely and effectively reduced acne by causing targeted cell death in sebaceous glands without side effects.
research Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
Blocking EGFR in skin cells doesn't majorly increase inflammation markers.
research Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
research The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
EGFR inhibitors can cause various skin issues during cancer treatment, and managing these is important for patient care.
research Cutaneous manifestations associated with immune checkpoint inhibitors
Immune checkpoint inhibitors can cause skin issues but are linked to better cancer outcomes.
research Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.